SCHEMBL1448563

SCHEMBL1448563

CC1(C)C=C(c2ccccc2N)CC(C)(C)C1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
HSD17B10 Q99714 2/20 0.35
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 2/20 0.33
GAA P10253 2/20 0.33
KMT2A Q03164 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.30
MEN1 O00255 1/20 0.30
MAPT P10636 1/20 0.30
RAB9A P51151 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
NOS2 P35228 1/20 0.30
CYP3A4 P08684 1/20 0.30
ALOX15 P16050 1/20 0.30
CASP1 P29466 1/20 0.30
CASP7 P55210 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4852681 0.79 HPGD (0.35) ALDH1A1L3MBTL1HSD17B10KDM4ENPC1
SCHEMBL4848347 0.77 CD44 (0.41) TDP1CYP3A4
SCHEMBL4850501 0.75 ALDH1A1 (0.43) ALDH1A1L3MBTL1HSD17B10KDM4ENPC1
Aniline SCHEMBL28164799 0.75 NPC1 (0.41) ALDH1A1HSD17B10NPC1RAB9ATDP1
SCHEMBL28096454 0.74 NPC1 (0.47) ALDH1A1NPC1SMN1; SMN2RAB9A
SCHEMBL14409165 0.72 PABPC1 (0.35) ALDH1A1
SCHEMBL25985762 0.71 ALDH1A1 (0.39) ALDH1A1L3MBTL1HSD17B10KDM4ENPC1
SCHEMBL4849563 0.70 HTR7 (0.51) MAPT
SCHEMBL3087574 0.66 ALDH1A1 (0.40) ALDH1A1L3MBTL1HSD17B10KDM4ENPC1
SCHEMBL9754961 0.64 PTGS1 (0.39) ALDH1A1NPC1SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910734-B2 Cell adhesion inhibitory action and cell infiltration inhibitory action; inflammatory, autoimmune diseases associated with adhesion and infiltration of leukocytes, inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosi EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-03-22 US disclosed
US-7910734-B2 Cell adhesion inhibitory action and cell infiltration inhibitory action; inflammatory, autoimmune diseases associated with adhesion and infiltration of leukocytes, inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosi EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-03-22 US disclosed
US-7910734-B2 Cell adhesion inhibitory action and cell infiltration inhibitory action; inflammatory, autoimmune diseases associated with adhesion and infiltration of leukocytes, inflammatory bowel disease, ulcerative colitis, Crohn's disease, irritable bowel syndrome, rheumatoid arthritis, psoriasis, multiple sclerosi EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-03-22 US disclosed
EP-1889827-B1 PROCESS FOR PRODUCING [2-(3,3,5,5-TETRAMETHYLCYCLOHEXYL)PHENYL]PIPERAZINE EISAI R&D MAN CO LTD (JP) 2010-08-25 EP disclosed
US-20090163715-A1 Intermediate in Production of [2-(3,3,5,5-Tetramethylcyclohexyl)phenyl]Piperazine Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-25 US disclosed
US-20090163715-A1 Intermediate in Production of [2-(3,3,5,5-Tetramethylcyclohexyl)phenyl]Piperazine Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-25 US disclosed
US-20090163715-A1 Intermediate in Production of [2-(3,3,5,5-Tetramethylcyclohexyl)phenyl]Piperazine Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-25 US disclosed
US-20080161566-A1 Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-07-03 US disclosed
US-20080161566-A1 Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-07-03 US disclosed
US-20080161566-A1 Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine EISAI R & D MANAGEMENT CO., LTD. (JP) 2008-07-03 US disclosed
EP-1889827-A1 INTERMEDIATE IN PRODUCTION OF [2-(3,3,5,5-TETRAMETHYLCYCLOHEXYL)PHENYL]PIPERAZINE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2008-02-20 EP disclosed
EP-1889827-A1 INTERMEDIATE IN PRODUCTION OF [2-(3,3,5,5-TETRAMETHYLCYCLOHEXYL)PHENYL]PIPERAZINE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2008-02-20 EP disclosed
EP-1832580-A1 CRYSTAL AND SALT OF 1-CYCLOPROPYLMETHYL-4-Ý2-(3,3,5,5)-TETRAMETHYLCYCLOHEXYL)PHENYL¨PIPERAZINE Eisai R&D Management Co., Ltd. (JP) 2007-09-12 EP disclosed
EP-1832580-A1 CRYSTAL AND SALT OF 1-CYCLOPROPYLMETHYL-4-Ý2-(3,3,5,5)-TETRAMETHYLCYCLOHEXYL)PHENYL¨PIPERAZINE Eisai R&D Management Co., Ltd. (JP) 2007-09-12 EP disclosed
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-12-07 US disclosed
EP-0623113-B1 PYRAZOLE CARBOXANILIDE FUNGICIDES MONSANTO CO (US) 1997-03-05 EP disclosed
US-5223526-A For plants MONSANTO COMPANY (US) 1993-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163715-A1 Intermediate in Production of [2-(3,3,5,5-Tetramethylcyclohexyl)phenyl]Piperazine Compound ICAM1, HRH1, HRH2 ALDH1A1 489/4885L3MBTL1 4129/4885HSD17B10 2543/4885
US-20080161566-A1 Crystal and Salt of 1-Cyclopropylmethyl-4-[2-(3,3,5,5-Tetramethylcyclohexyl)Phenyl]Piperazine ICAM1, IL5, VCAM1 ALDH1A1 1199/4885L3MBTL1 3721/4885HSD17B10 3606/4885
US-20060276465-A1 1,2-di(cyclic) substituted benzene compounds HRH3, CCR10, HRH1 ALDH1A1 617/4885L3MBTL1 3780/4885HSD17B10 498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.